Trial Profile
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 13 Nov 2018 Results (n=264) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2017 Results (n=111) assessing safety and efficacy in infected population from Singapore, Malaysia, Thailand, and Vietnam presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases